Effects of Bone Morphogenetic Protein Agonist Small Molecule, SB4, on Osteogenic Differentiation of Adipose-Derived Mesenchymal Stem Cells
Open Access
- 28 February 2026
- journal article
- Published by Korean Society for Bone and Mineral Research in Journal of Bone Metabolism
- Vol. 33 (1) , 18-29
Abstract
Background: Bone morphogenetic protein (BMP) signaling is crucial for osteogenic (OS) differentiation, bone growth, and repair. However, the clinical use of BMPs is limited due to their cost and challenges in delivery. SB4, a potent compound of benzoxazole, is a newly introduced small molecule shown to activate the BMP signaling pathway. In this study, we investigated the effects of SB4 on OS differentiation of adipose-derived mesenchymal stem cells (ADMSCs).Methods: We first examined whether BMP signaling is active in osteoinduced ADMSCs. ADMSCs were treated with SB4 (5 and 10 μM) for 24 hr, and mRNA expression of BMP direct target genes (ID1 and ID3) was analyzed. ADMSCs were then cultured with or without SB4 (10 μM) for 7, 14, and 21 days, followed by Alizarin red staining and real-time polymerase chain reaction analysis of mRNA expression of OS markers RUNX2, BMP2, alkaline phosphatase (ALP), and Osteopontin. To investigate the most effective time period of SB4 in osteogenesis, SB4 was applied every 3.5 days during the 21-day differentiation period.Results: After 24 hr of treatment with SB4 (5 and 10 μM), increased mRNA expression of BMP direct target genes (ID1 and ID3) confirmed that SB4 acts as an active BMP agonist. SB4-treated ADMSCs showed enhanced bone matrix production and increased mRNA expression of RUNX2, BMP2, ALP, and Osteopontin. Increased mRNA expression of OS markers, bone matrix formation, and ALP activity during the first 7 days of SB4 treatment suggested the importance of SB4 at the early stage of differentiation.Conclusions: These results indicate that SB4, with potential BMP-like activity, induces OS differentiation of ADMSCs, leading it to serve as a cost-effective BMP agonist for osteogenesis-related research as well as a potential therapeutic agent for bone repair and regeneration.Keywords
Funding Information
- Council for Development of Regenerative Medicine and Stem Cell technologies and University of Tehran
This publication has 53 references indexed in Scilit:
- Bone induction and defect repair by true bone ceramics incorporated with rhBMP-2 and SrJournal of Materials Science: Materials in Medicine, 2021
- Preface to the Fourth Edition2019
- Bone morphogenetic protein receptor signal transduction in human diseaseThe Journal of Pathology, 2018
- Clinical application of bone morphogenetic proteins for bone healing: a systematic reviewInternational Orthopaedics, 2017
- A synthetic compound that potentiates bone morphogenetic protein-2-induced transdifferentiation of myoblasts into the osteoblastic phenotypeMolecular and Cellular Biochemistry, 2010
- Development and optimization of a cell‐based assay for the selection of synthetic compounds that potentiate bone morphogenetic protein‐2 activityCell Biochemistry and Function, 2009
- Prevalence, Complications, and Hospital Charges Associated With Use of Bone-Morphogenetic Proteins in Spinal Fusion ProceduresJAMA, 2009
- Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trialBone, 2008
- Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacyOsteoporosis International, 2008
- Salmon calcitonin: a review of current and future therapeutic indicationsOsteoporosis International, 2007